Up until now, people living with HIV suppress the virus with a regimen of three or four pills.
The FDA just approved a new combination of drugs to treat HIV.
The treatment uses two drugs instead of three or more, which has been the standard.
The new approval could shake up the $22 billion HIV drug market.
The FDA approved a two-drug regimen for HIV for the first time on Tuesday.
The pill, which contains dolutegravir with rilpivirine, is made by ViiV, the specialist HIV company majority owned by GlaxoSmithKline, that has Pfizer and Japanese pharmaceutical company Shionogi as shareholders.
Up until now, people living with HIV suppress the virus with a regimen of three or four pills. Keeping the amount of HIV in the blood low is key for suppressing symptoms of the virus.
Tech: A new drug to treat HIV just got approved — and it could shake up a $22 billion market
